COVID-19: Ethical challenges of vaccinating people with comorbidities
Unlike in other groups, national databases of people with comorbidities are not available. However, though not comprehensive, since 2010, State
Read More
Author: Prasad Ravindranath
Can COVID-19 vaccines with EUA be used at the population level?
Meanwhile, the Indian government has spelt out four high-risk groups — healthcare workers, frontline workers, those over 50 years of
Read More
By putting the vaccine approval on hold for want of data, DCGI has underscored its priorities
The greatly reassuring decision to seek additional safety and immunogenicity data from the Pune-based Serum Institute of India and Hyderabad’s
Read More
Transparency in COVID-19 vaccine trials vital to gain public trust
Unlike Pfizer, AstraZeneca, which is carrying out the phase-3 trials of the Oxford vaccine in four countries, is yet to
Read More
COVID-19: Challenges in achieving herd immunity through vaccination
But the government’s idea of vaccinating a “critical mass of people” for the purpose of breaking the virus transmission chain
Read More
Why working alongside China to uncover the virus’s origin is important
Knowing the natural reservoirs and intermediate hosts and the events that permitted the virus to jump across the species barrier
Read More
Moderna’s mRNA vaccine has 94.1% efficacy in final analysis, has applied for EUA
According to the release, the Phase-3 trial has exceeded two months of median follow-up post vaccination as required by the U.S. FDA
Read More
Oxford vaccine shows 90% efficacy in Phase-3 trial
Two doses of the vaccine given in two different regimen showed different efficacies. In the case of the regimen (involving
Read More
Ethics of denying COVID-19 vaccine to placebo group participants once EUA is granted
Offering the vaccine right away to those in the placebo group will first require unblinding the study. Unblinding the study and offering the vaccine to the placebo group will make it almost impossible to gather further information on vaccine efficacy, thus making full licensure challenging.
Read More
Oxford vaccine found safe and immunogenic even in older adults
The results were published online in The Lancet on November 19. The results are based on the study of 560
Read More
Pfizer’s mRNA vaccine 95% efficacious, final analysis shows
On November 18, Pfizer announced that the final efficacy analysis of its candidate mRNA-based vaccine (BNT162b2) in phase-3 trial has
Read More
More mRNA COVID-19 vaccines show stability at higher temperatures
The interim results of Moderna’s mRNA vaccine show that the vaccine has 94.5% efficacy in preventing COVID-19. The interim analysis,
Read More
Pfizer’s COVID-19 vaccine shows promise, many unknowns remain
The results of the Phase-1 trial, announced in August, first through a press release and then through a preprint a
Read More